Skip to main content

Veletri Side Effects

Generic name: epoprostenol

Medically reviewed by Drugs.com. Last updated on Aug 27, 2023.

Note: This document contains side effect information about epoprostenol. Some dosage forms listed on this page may not apply to the brand name Veletri.

Applies to epoprostenol: intravenous powder for solution.

Serious side effects of Veletri

Along with its needed effects, epoprostenol (the active ingredient contained in Veletri) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking epoprostenol:

More common

Less common

Incidence not known

Other side effects of Veletri

Some side effects of epoprostenol may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to epoprostenol: intravenous powder for injection.

General

The most frequently reported side effects during initiation and dose escalation were nausea, vomiting, headache, hypotension, flushing, chest pain, anxiety, dizziness, bradycardia, dyspnea, abdominal pain, musculoskeletal pain, and tachycardia.

The most frequently reported side effects during chronic dosing were jaw pain, headache, flushing, diarrhea, nausea, vomiting, flu-like symptoms, and anxiety/nervousness.[Ref]

Cardiovascular

Very common (10% or more): Palpitation (63%), flushing (up to 58%), cyanosis (up to 54%), tachycardia (up to 35%), pallor (up to 32%), hypotension (up to 27%), right heart failure (up to 25%), heart failure (23%)

Common (1% to 10%): Bradycardia, myocardial infarction, shock, peripheral vascular disorder, vascular disorder

Postmarketing reports: High output cardiac failure[Ref]

Nervous system

Very common (10% or more): Dizziness (up to 83%), headache (up to 83%), tremor (21%), hyperkinesia (up to 21%), syncope (up to 13%), hypesthesia (up to 12%), paresthesia (up to 12%), hyperesthesia (12%)[Ref]

Gastrointestinal

Very common (10% or more): Nausea/vomiting (up to 67%), esophageal reflux/gastritis (61%), diarrhea (up to 50%), ascites (up to 23%)

Common (1% to 10%): Abdominal pain, dyspepsia, abdominal colic

Uncommon (0.1% to 1%): Dry mouth

Postmarketing: Hepatic failure[Ref]

Musculoskeletal

Very common (10% or more): Pain/neck pain/arthralgia (up to 84%), nonspecific musculoskeletal pain (up to 84%), jaw pain (up to 75%), myalgia (44%)

Common (1% to 10%): Back pain, leg cramp

Frequency not reported: Collagen disease[Ref]

Other

Very common (10% or more): Weight decreased (45%), pain (up to 29%), chills/fever/sepsis/flu-like symptoms (25%), fever (21%), hemorrhage/ hemorrhage injection

site/ hemorrhage rectal (11%), chest pain (11%)

Common (1% to 10%): Asthenia, sepsis, septicemia, procedural complication

Very rare (less than 0.01%): Lassitude

Frequency not reported: Fatigue, edema, catheter-related infection[Ref]

Hematologic

Common (1% to 10%): Thrombocytopenia, bleeding

Postmarketing reports: Anemia, hypersplenism, pancytopenia, splenomegaly[Ref]

Endocrine

Very rare (less than 0.01%): Hyperthyroidism[Ref]

Respiratory

Very common (10% or more): Hypoxia (up to 55%)

Common (1% to 10%): Dyspnea, pneumothorax, hemothorax, cough increased, epistaxis, pharyngitis, pleural effusion, sinusitis, pulmonary edema, respiratory disorder

Postmarketing reports: Pulmonary embolism[Ref]

Local

Very common (10% or more): Infection (18%), pain (up to 13%)

Very rare (less than 0.01%): Erythema[Ref]

Psychiatric

Very common (10% or more): Anxiety/nervousness (up to 21%), depression (up to 13%), agitation (11%)

Common (1% to 10%): Insomnia

Postmarketing reports: Acute confusional state[Ref]

Dermatologic

Very common (10% or more): Skin ulcer (39%), eczema/rash/urticaria (up to 25%)

Common (1% to 10%): Sweating, cellulitis[Ref]

Genitourinary

Common (1% to 10%): Hematuria, urinary tract infection[Ref]

Hepatic

Postmarketing reports: Hepatic failure[Ref]

Metabolic

Very common (10% or more): Anorexia (up to 66%)

Common (1% to 10%): Hyperkalemia, hypercalcemia

Frequency not reported: Blood glucose increased[Ref]

References

1. Product Information. Flolan (epoprostenol). Glaxo Wellcome. 2001.

2. Cerner Multum, Inc. UK Summary of Product Characteristics.

3. Cerner Multum, Inc. Australian Product Information.

4. Product Information. Epoprostenol Sodium (epoprostenol). Teva Pharmaceuticals USA. 2017.

5. Product Information. Veletri (epoprostenol). Actelion Pharmaceuticals US Inc. 2017.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.